Effects of Direct Acting Antivirals on Glomerular Filtration Rates and Neutrophil Gelatinase-Associated Lipocalin during the Treatment of Hepatitis C Patients

Abstract

epatitis C viral infection is one of the most common chronic viral infections worldwide with a significant burden in Egypt, which had no definite curative treatment until the last decade. However the development of the direct acting antivirals targeting HCV has revolutionized the treatment protocol, attributing to a great incline in viral eradication achieving sustained virological responses of over 90% with different DAA regimens. There were some concerns regarding the safety of some DAAs on renal functions, with contradicting results in a few studies. Our study was a prospective cohort study conducted in Ain Shams university viral hepatitis treatment and research center during the period from October 2018 to June 2020. The aim of this study was to evaluate the impact of the most widely used direct acting antiviral in our center sofosbuvir + daclatasvir and Ombitasvir/Paritaprevir/Ritonavir + Ribavirin on glomerular filtration rates and neutrophil gelatinase-associated lipocalin, as a marker of tubular injury during the treatment of hepatitis C patients, with comparison between these 2 regimens. The study was performed on 80 Egyptian patients who were ≥18years of age and had chronic infection with hepatitis C treated with combination of IFN-free DAAs, and 20 healthy control subjects.